Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042406 · ClinicalTrials.gov registry record · Phase 2
Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker
A Phase 2 study, sponsored by Genmab.
- Terminated
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT00042406 is a Phase 2 study that was terminated before completion, run by Genmab. The registered enrollment target is 83 participants.
The verdict
NCT00042406, a Phase 2 study, was terminated before completion, sponsored by Genmab.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether HuMax-CD4 is effective in the treatment of active RA in participants who have failed treatment with MTX and at least one TNF-alpha blocking agent.
Interventions
- DRUG Placebo
- DRUG HuMax-CD4
- DRUG Humax-CD4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2002-03-04 |
| Est. Completion | 2003-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00042406
The ClinicalTrials.gov registry entry for NCT00042406 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00042406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00042406 about?
NCT00042406 is a clinical study titled "Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker". The purpose of this study is to determine whether HuMax-CD4 is effective in the treatment of active RA in participants who have failed treatment with MTX and at least one TNF-alpha blocking agent.
What is the current status of trial NCT00042406?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2002-03-04. Estimated completion is 2003-03-31.
What interventions are being tested in trial NCT00042406?
The interventions under investigation include: Placebo (DRUG), HuMax-CD4 (DRUG), Humax-CD4 (DRUG).
Who is sponsoring clinical trial NCT00042406?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.